- North America
- Other regions
PROGENIKA’s BLOOD GROUP GENOTYPING TEST AVAILABLE THROUGH ARUP LABORATORIESCambridge, MA, October 22, 2009 – Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations. Progenika’s blood group genotyping microarray, which simultaneously detects over 100 genetic variants in the nine blood group systems that are most relevant to transfusion safety, overcomes these serological limitations. |
Progenika’s mission is to improve healthcare through the development and commercialization of diagnostic and prognostic products to personalize the treatment of genetically complex diseases.
Progenika’s core business is the design and production of genotyping microarrays to be used in the diagnosis and prognosis of genetically complex diseases and predicting response to therapy.
Two diagnostic tests are available in the United States. Autosomal Dominant Hypercholesterolemia, a diagnostic test for Familial Hypercholesterolemia and the Blood Group Genotyping test, for the identification of blood groups.
In addition, Progenika's pipeline includes a series of new genotyping tools for the diagnosis and prognosis of prostate cancer, multiple sclerosis, rheumatoid arthritis and osteoporosis, among others.